Fig. 2: Disruption of PSD95/nNOS with ZL006 does not have the non-specific behavioral effects seen with NMDARs antagonist MK-801.

a Animals received i.p. injections 1 h prior to the OF Test. MK-801-treated animals displayed increased locomotor activity (F_{2, 25} = 7.562, P < 0.01). SI test b was performed 5 min after OF test. MK-801-treated animals showed decreased social activity (F_{2, 25} = 9.548, P < 0.001). n = 14, 6, and 8 for control, ZL006 and MK801, respectively. c In NORT, animals received i.p. injections immediately after the familiarization trial and the testing trial was conducted after a 3 h ITI. Discrimination index expressed by different groups of rats during the testing trial showed that MK-801 treated rats displayed deficits in the discrimination behavioral (n = 11, 9, and 9 for control, ZL006 and MK801, respectively; F_{2, 26} = 5.993, P < 0.01). d In the Y-maze test, the animals received i.p. injections immediately after the familiarization trial and the testing trial was conducted after a 1 h ITI. n = 6 for each group. Left: rats in the vehicle and ZL006 treated groups visited novel arm more than the other two arms (P < 0.05); however, animals treated with MK-801 visited novel arm less that the other arms (P < 0.05); Right: controls and ZL006 treated rats spent more time in the novel arm than the other arms (P < 0.01); no arm difference was found in the rats treated with MK-801 (P > 0.05). *P < 0.05, **P < 0.01; ITI inter-trial interval, OF open field, SI social interaction, NORT novel object recognition